Newly released data reveals that seven out of 67 children treated with Bluebird Bio Inc's (NASDAQ:BLUE) gene therapy for a severe neurological disorder in clinical trials have developed blood cancers.

Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases resolved after treatment.

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and Skysona.

A Bluebird Bio gene therapy has helped children with a devastating neurological disorder, but seven have developed blood cancer, creating difficult choices for the families.